ZA90245B - Treatment of diseases associated with hiv infections - Google Patents

Treatment of diseases associated with hiv infections

Info

Publication number
ZA90245B
ZA90245B ZA90245A ZA90245A ZA90245B ZA 90245 B ZA90245 B ZA 90245B ZA 90245 A ZA90245 A ZA 90245A ZA 90245 A ZA90245 A ZA 90245A ZA 90245 B ZA90245 B ZA 90245B
Authority
ZA
South Africa
Prior art keywords
treatment
diseases associated
hiv infections
hiv
infections
Prior art date
Application number
ZA90245A
Other languages
English (en)
Inventor
Wulf Droge
Droge Wulf
Leonard A Herzenberg
A Herzenberg Leonard
Leonore A Herzenberg
A Herzenberg Leonore
Original Assignee
Zambon Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zambon Spa filed Critical Zambon Spa
Publication of ZA90245B publication Critical patent/ZA90245B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ZA90245A 1989-01-26 1990-01-12 Treatment of diseases associated with hiv infections ZA90245B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30239689A 1989-01-26 1989-01-26

Publications (1)

Publication Number Publication Date
ZA90245B true ZA90245B (en) 1990-10-31

Family

ID=23167578

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA90245A ZA90245B (en) 1989-01-26 1990-01-12 Treatment of diseases associated with hiv infections

Country Status (25)

Country Link
US (1) US5607974A (nl)
JP (1) JPH04504570A (nl)
KR (1) KR940002820B1 (nl)
AU (1) AU639686B2 (nl)
BE (1) BE1004168A3 (nl)
CA (3) CA1339256C (nl)
CH (1) CH683499A5 (nl)
DE (1) DE4090165T (nl)
DK (1) DK139191A (nl)
FR (1) FR2643557B1 (nl)
GB (1) GB2243296B (nl)
GR (1) GR900100048A (nl)
IE (1) IE62795B1 (nl)
IL (1) IL93162A (nl)
IT (1) IT1237999B (nl)
LU (1) LU87977A1 (nl)
MA (1) MA21739A1 (nl)
MX (1) MX173567B (nl)
NL (1) NL9020094A (nl)
OA (1) OA09503A (nl)
PT (1) PT92949B (nl)
SE (1) SE9101815D0 (nl)
TN (1) TNSN90009A1 (nl)
WO (1) WO1990008540A1 (nl)
ZA (1) ZA90245B (nl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554655A (en) * 1991-09-30 1996-09-10 Jess G. Thoene Method of treating HIV infection
MX9205549A (es) * 1991-09-30 1993-05-01 Jess G Thoene Metodo para el tratamiento de vih.
EP0600462A1 (en) * 1992-12-01 1994-06-08 Nippon Flour Mills Co., Ltd. Reverse transcriptase inhibitors and antiviral agents
AU6060694A (en) * 1993-05-10 1994-11-17 Transcend Therapeutics, Inc Method for treating acquired immune deficiency syndrome
DE4325547C2 (de) * 1993-07-29 1997-11-27 Max Planck Gesellschaft Verwendung von Thiolverbindungen zur Therapie von Hepatitis-_Viren-induzierten Erkrankungen
US5725870A (en) * 1993-10-15 1998-03-10 Thoene; Jess G. Methods, composites and articles for contraception
CA2173964A1 (en) * 1993-10-15 1995-04-20 Jess G. Thoene Prevention of hiv infection
US5786152A (en) * 1996-04-26 1998-07-28 Amgen Inc. Methods of inhibiting syp binding to a CTLA-4 receptor
HUP9602024A3 (en) * 1996-07-25 1999-05-28 Toth Sandor Pharmaceutical composition containing aminoacid for external use
TW517089B (en) 1996-09-03 2003-01-11 Res Dev Foundation Assessment of intracellular cysteine and glutathione concentrations
ATE444760T1 (de) * 1997-01-13 2009-10-15 Univ Emory Glutathion zur behandlung von influenzainfektionen
US6331610B1 (en) * 1997-04-25 2001-12-18 Metatron, Inc. Method for treating AIDS and HIV infection using select peptides from the beta subunit of human chorionic gonadotropin
US6020205A (en) * 1998-04-10 2000-02-01 Immunosciences Lab, Inc. Determination of intracellular antioxidant levels
US6251868B1 (en) * 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
US6355682B1 (en) * 2001-05-11 2002-03-12 Assa Weinberg Treatment of acute renal failure by administration of N-acetylcysteine
ITMI20011863A1 (it) * 2001-09-05 2003-03-05 Zambon Spa Associazione di farmaci contro il virus dell'influenza
WO2005017094A2 (en) * 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
ES2393674T3 (es) 2003-11-14 2012-12-27 Brigham And Women's Hospital, Inc. Métodos para modular la inmunidad
ITMI20032528A1 (it) * 2003-12-19 2005-06-20 Francesco Santangelo Uso di cistina o di cisteina per la prevenzione e il
US20070053970A1 (en) * 2005-05-25 2007-03-08 Guilford F T Liposomal formulation for oral administration of glutathione (reduced) and/or methylcobalamine for diseases related to glutathione deficiency and deficiency of the methionine remethylation pathway

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) * 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4440788A (en) * 1980-05-13 1984-04-03 Mitsubishi Chemical Industries, Limited Cysteine derivatives
US4335210A (en) * 1981-02-11 1982-06-15 Cornell Research Foundation Method of producing L-cysteine
US4665082A (en) * 1981-02-11 1987-05-12 Cornell Research Foundation Cysteine delivery system
US4434158A (en) * 1981-02-11 1984-02-28 Cornell Research Foundation Cysteine delivery system
US4647571A (en) * 1981-02-11 1987-03-03 Cornell Research Foundation Cysteine delivery composition
US4438124A (en) * 1981-02-11 1984-03-20 Cornell Research Foundation, Inc. Cysteine delivery system
US4879370A (en) * 1983-12-02 1989-11-07 Cornell Research Foundation, Inc. Glutathione delivery system
US4767785A (en) * 1984-01-18 1988-08-30 Michael Georgieff Hypocaloric preparation and intravenous method for hypocaloric treatment of patients
US4744989A (en) * 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4710489A (en) * 1985-04-22 1987-12-01 Cornell Research Foundation, Inc. Glutathione delivery system
US4758551A (en) * 1986-07-08 1988-07-19 Cornell Research Foundation, Inc. Methods for combatting renal toxicity due to metals or nephrotoxic drugs and for selectively modulating in vivo formation of leukotriene types
DE3707127C2 (de) * 1987-03-05 1996-06-20 Zambon Spa Verwendung von Methionin zur Behandlung von Immun-Schwächeerkrankungen bei Virusinfektionen und/oder bei Tumorerkrankungen
DE3812008A1 (de) * 1987-04-10 1988-10-20 Pfrimmer Pharma Verwendung von l-(-)-thiazolidin-4-carbonsaeure als cysteinquelle bei gestoerter cysteinsynthese
US4895716A (en) * 1987-06-09 1990-01-23 Biogen, Inc. Stabilized formulations of gamma interferons
DE3906671A1 (de) * 1989-03-02 1990-09-06 Wulf Prof Dr Droege Orales, magenvertraegliches n-acetylcysteinpraeparat hoher dosierung

Also Published As

Publication number Publication date
CA1339070C (en) 1997-07-29
GR900100048A (el) 1991-06-07
LU87977A1 (fr) 1992-03-11
DK139191D0 (da) 1991-07-25
GB9112420D0 (en) 1991-07-31
MA21739A1 (fr) 1990-10-01
SE9101815L (sv) 1991-06-13
PT92949B (pt) 1995-12-29
JPH04504570A (ja) 1992-08-13
GB2243296A (en) 1991-10-30
OA09503A (en) 1992-11-15
SE9101815D0 (sv) 1991-06-13
KR940002820B1 (ko) 1994-04-04
PT92949A (pt) 1990-07-31
IL93162A0 (en) 1990-11-05
AU4969490A (en) 1990-08-24
IT9019141A1 (it) 1991-07-24
US5607974A (en) 1997-03-04
CA2045180A1 (en) 1990-07-27
IL93162A (en) 1995-03-15
TNSN90009A1 (fr) 1991-03-05
FR2643557B1 (fr) 1995-02-03
AU639686B2 (en) 1993-08-05
CA1339256C (en) 1997-08-12
IT9019141A0 (it) 1990-01-24
GB2243296B (en) 1992-10-21
DK139191A (da) 1991-07-25
WO1990008540A1 (en) 1990-08-09
MX173567B (es) 1994-03-16
IT1237999B (it) 1993-06-21
NL9020094A (nl) 1991-10-01
IE900073L (en) 1990-07-26
KR910700045A (ko) 1991-03-13
DE4090165T (nl) 1991-11-21
BE1004168A3 (fr) 1992-10-06
FR2643557A1 (fr) 1990-08-31
IE62795B1 (en) 1995-03-08
CH683499A5 (it) 1994-03-31

Similar Documents

Publication Publication Date Title
ZA90245B (en) Treatment of diseases associated with hiv infections
AP9000206A0 (en) Treatment of conditions & diseases
ZA872624B (en) Medicament for the treatment of inflammations of the eye
IL85646A (en) Therapeutic composition for the treatment of retroviral infections comprising a retroviral compound and a mismatched dsrna
EP0251434A3 (en) Treatment of fungal infections
EP0559791A4 (en) Treatment of topical infections
US5011841B1 (en) Treatment of depression
AU8185491A (en) Treatment of disease
EP0294538A3 (en) Use of nigericin in the treatment of viral diseases
EP0411900A3 (en) Treatment of conditions involving excessive eating
EP0491873A4 (en) Therapeutic compositions; methods for treatment of hiv infections
EP0655919A4 (en) TREATMENT OF VIRAL INFECTIONS IN MAN.
GB8611746D0 (en) Treating skin infections
EP0248361A3 (en) Pharmaceutical preparation for the treatment of bacterial infections
GB8710664D0 (en) Self-administration of ocular treatment materials
IE892991L (en) Treatment of viral infections
AP9000180A0 (en) Pharmaceutical composition for the treatment of protozoal diseases
IE880770L (en) Treatment of viral infections
IE892593L (en) Treatment of virus diseases
ZA908094B (en) Treatment of hiv infections and compounds useful therein
ZA872553B (en) Treatment of fungal infections
ZA896503B (en) Pharmaceutical combination preparations and their use for the prophylaxis or treatment of bacterial infectious diseases
BG52099B2 (en) Gel for the treatment of skin viral infections
GB8629432D0 (en) Treating skin virus infections
AU6726490A (en) Treatment of articles